Hyperparathyroidism Market Size in the 7MM is projected to grow at a CAGR of 1.2% by 2034, estimates DelveInsight

DelveInsight's "Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast- 2034′′ report offers an in-depth understanding of the Hyperparathyroidism, historical and forecasted epidemiology as well as the Hyperparathyroidism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Unlock key insights into the Hyperparathyroidism Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ https://www.delveinsight.com/sample-request/hyperparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hyperparathyroidism Market Report
• In December 2025, Amgen announced a Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis.
• In December 2025, Shanghai Hengrui Pharmaceutical Co. Ltd conducted a study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
• In 2024, the United States dominated the hyperparathyroidism market among the 7MM, capturing approximately 80% of the total market share.
• In 2024, the PARSABIV represented approximately 50% of the market share across the EU4 and the UK.
• In 2024, the secondary hyperparathyroidism type accounted for approximately 261,000 cases of hyperparathyroidism cases in Japan.
• In 2024, the total diagnosed prevalent cases of hyperparathyroidism in the United States stood at 2,607,000
• In 2024, individuals aged ≥60 years accounted for the highest number of cases
• In 2024, aproximately 70% of hyperparathyroidism cases accounted by females in 7MM.
• In Japan, the diagnosed prevalence of Hyperparathyroidism was approximately 479,000 in 2024.
• The leading Hyperparathyroidism Companies such as Vidasym Inc., Mitsubishi Tanabe Pharma, Shanghai Hengrui Pharmaceutical and others.
• Promising Hyperparathyroidism Therapies such as KHK7580, AMG 073, SK-1403, Cinacalcet, Etelcalcetide, ASP7991, DP001, Sensipar (Cinacalcet HCl) and others.

Stay ahead in the competitive landscape of the Hyperparathyroidism Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ https://www.delveinsight.com/sample-request/hyperparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hyperparathyroidism Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Hyperparathyroidism
• Total Diagnosed Prevalence Cases of Hyperparathyroidism
• Type-Specific Cases of Hyperparathyroidism
• Age-specific Cases of Hyperparathyroidism
• Gender-specific Cases of Hyperparathyroidism
• Total Treated cases of Hyperparathyroidism

Download the report to understand which factors are driving Hyperparathyroidism epidemiology trends @ https://www.delveinsight.com/sample-request/hyperparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hyperparathyroidism Marketed Therapies
• PARSABIV (Etelcalcetide): Amgen & Ono Pharmaceutical
PARSABIV is a novel calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) on hemodialysis. A calcimimetic is a drug that mimics the action of calcium by activating the calcium-sensing receptors on the parathyroid gland. PARSABIV binds to and activates the calcium-sensing receptor on the parathyroid gland, thereby decreasing PTH levels.

• UPASITA (Upacicalcet): SANWA KAGAKU KENKYUSHO
UPASITA (Upacicalcet) is an intravenous calcimimetic agent being developed by Sanwa Kagaku Kenkyusho, under license from EA Pharma, for the treatment of secondary hyperparathyroidism, a common and early complication of chronic kidney disease, in patients undergoing haemodialysis. By acting directly on parathyroid cell membrane calcium-sensing receptors, upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels.

Hyperparathyroidism Market Insights
Advanced imaging techniques, such as sestamibi scans, high-resolution ultrasound, and 4D-CT, aid in preoperative localization but may not always yield conclusive results. Surgical removal of the hyperfunctioning parathyroid gland(s) remains the definitive treatment, offering a potential cure. However, localization of the hyperfunctioning gland can be complex, particularly in cases involving small adenomas, ectopic lesions, or multiglandular disease. Advanced imaging techniques, such as sestamibi scans, high-resolution ultrasound, and 4D-CT, aid in preoperative localization but may not always yield conclusive results. The treatment landscape for hyperparathyroidism has evolved significantly, particularly with the advent of calcimimetics and refined surgical techniques.

Discover the future of Hyperparathyroidism treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ https://www.delveinsight.com/sample-request/hyperparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hyperparathyroidism Market Outlook
Each type requires distinct management strategies, ranging from surgical intervention in PHPT to medical therapies such as phosphate binders, vitamin D analogs, and calcimimetics in SHPT and THPT. Early diagnosis and targeted treatment are essential to prevent complications such as osteoporosis, nephrolithiasis, cardiovascular risks, and metabolic disturbances. Surgical removal of the hyperfunctioning parathyroid gland(s) remains the definitive treatment, offering a potential cure. However, localization of the hyperfunctioning gland can be complex, particularly in cases involving small adenomas, ectopic lesions, or multiglandular disease.

Hypoparathyroidism Therapies and Companies
• TransCon PTH: Ascendis Pharma
• EB612: EnteraBio
• Encaleret: Bridgebio/Calcilytix Therapeutics

Hypoparathyroidism Market Drivers
• Rising prevalence of neck surgeries and autoimmune diseases
• Rising awareness
• Presence of major companies

Explore the dynamics of the Hyperparathyroidism Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ https://www.delveinsight.com/sample-request/hyperparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hyperparathyroidism Market Report
• Study Period- 2020-2034
• Coverage: 7MM
• Hyperparathyroidism Companies- Vidasym Inc., Mitsubishi Tanabe Pharma, Shanghai Hengrui Pharmaceutical and others.
• Hyperparathyroidism Therapies- KHK7580, AMG 073, SK-1403, Cinacalcet, Etelcalcetide, ASP7991, DP001, Sensipar (Cinacalcet HCl) and others.
• Hyperparathyroidism Therapeutic Assessment: Hyperparathyroidism current marketed and Hyperparathyroidism emerging therapies
• Hyperparathyroidism Market Dynamics: Hyperparathyroidism market drivers and Hyperparathyroidism market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hyperparathyroidism Unmet Needs, KOL's views, Analyst's views, Hyperparathyroidism Market Access and Reimbursement

Table of Contents
1. Hyperparathyroidism Market Report Introduction
2. Executive Summary for Hyperparathyroidism
3. SWOT analysis of Hyperparathyroidism
4. Hyperparathyroidism Patient Share (%) Overview at a Glance
5. Hyperparathyroidism Market Overview at a Glance
6. Hyperparathyroidism Disease Background and Overview
7. Hyperparathyroidism Epidemiology and Patient Population
8. Country-Specific Patient Population of Hyperparathyroidism
9. Hyperparathyroidism Current Treatment and Medical Practices
10. Hyperparathyroidism Unmet Needs
11. Hyperparathyroidism Emerging Therapies
12. Hyperparathyroidism Market Outlook
13. Country-Wise Hyperparathyroidism Market Analysis
14. Hyperparathyroidism Market Access and Reimbursement of Therapies
15. Hyperparathyroidism Market Drivers
16. Hyperparathyroidism Market Barriers
17. Hyperparathyroidism Appendix
18. Hyperparathyroidism Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.